AMG 319 Lymphoid Malignancy FIH

NCT01300026 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Chronic Lymphocytic Leukemia
Diffuse Large Cell Lymphoma
Hematologic Malignancies
Hematology
Leukemia
Low Grade Lymphoma
Lymphoma
Mantle Cell Lymphoma
Non-Hodgkin's Lymphoma
Oncology
Oncology Patients
T Cell Lymphoma
Tumors

Interventions

DRUG: AMG 319

Sponsor

Amgen